Help us enhance future SAHF MASAC events by sharing your valuable insights. Your feedback is crucial in shaping the direction of our symposiums and ensuring that we continue to deliver high-quality, relevant, and impactful experiences for all attendees. Please take a few moments to complete the survey and let your voice be heard. Together, let's pave the way for a brighter future in haemophilia care.
SAHF MASAC Educational Symposium is made possible by generous sponsorships from these companies and organisations.
The South African Haemophilia Foundation is a non-profit organization that was established in 1970. The foundation is dedicated to advocating for the needs of the bleeding disorders community in South Africa. SAHF's mission is to ensure that people with bleeding disorders have access to appropriate and quality care, education, and support.
National Bioproducts Institute NPC (NBI) is a South African pharmaceutical company, and the only plasma fractionator in Africa. NBI is located in Pinetown, KwaZulu Natal and our core business is the manufacture of bio-pharmaceutical products, using bioprocessing methods to isolate and refine therapeutic proteins from human plasma into plasma-derived biopharmaceutical products. In addition, NBI develops and manufactures diagnostic kits and monoclonal antibodies for the South African and international diagnostics market, as well as for in-house quality control testing and the testing of human plasma, using biotechnology processes. The majority of NBI’s raw material used in its core business is human plasma supplied mainly by South African National Blood Service and the Western Province Blood Transfusion Service.
At Roche, finding innovative solutions for those affected by diseases of the blood is not only a priority, it’s in our blood. Our commitment extends beyond developing innovative therapies, to playing a wider role in improving patient’s quality of life. We are exploring the best ways to deliver innovations to patients as quickly and effectively as possible, which includes evolving and improving how our clinical trials are designed and how our therapies are administered. We are also looking at new ways to measure treatment success through the use of alternative clinical endpoints. We continue to invest in bringing innovative treatment options to people with diseases of the blood, as our teams strive to continually deliver transformational change for patients and the physicians who treat them.
Novo Nordisk Rare Disease is a speciality care unit focused on generating scientific and technological breakthroughs for people living with a rare and ultra-rare diseases. We have a 40-year legacy and expertise in rare blood and endocrine disorders, which make us perfectly placed to drive innovations to lessen the burden and truly achieve life-changing benefits for people living with a rare disease - a population where the unmet need remains high and collectively affect around 350 million people across the globe.